Artemis Laboratories Nigeria recently welcomed a delegation from Dr. Reddy’s for a detailed visit and inspection of its manufacturing facility in Ota, Ogun State–a step forward in a relationship that could see the two companies collaborate more closely on pharmaceutical production in Nigeria.
Dr. Reddy’s Laboratories is one of the world’s major pharmaceutical companies–a Hyderabad-based, globally listed manufacturer with operations spanning more than 25 countries, known for its work across generics, active pharmaceutical ingredients (APIs), and biosimilars. For a local manufacturer like Artemis, a working relationship with a company of this scale is significant: it opens the door to higher manufacturing standards, deeper technical knowledge-sharing, and access to production opportunities that reach far beyond Nigeria’s borders.
The visit’s specific focus–assessing Artemis’s readiness to produce lenacapavir tablets–adds further weight to the occasion. Lenacapavir is among the most closely watched treatments in global health right now, and interest from a manufacturer of Dr. Reddy’s standing signals real confidence in what Artemis has built in Ota.
Artemis Lab manufactures oral liquid and oral solid dosage forms–including analgesics, hematinics, antacids, cough mixtures, antimalarials, and antimicrobial agents–in line with Good Manufacturing Practice standards, supporting local pharmaceutical production in Nigeria.
The visit centred on assessing the factory’s manufacturing capability, regulatory readiness, and quality systems, with particular focus on the plant’s readiness to produce lenacapavir tablets. The Dr. Reddy’s team toured production areas, warehouse and storage spaces, quality control facilities, and documentation points, reviewing everything from hygiene controls and material flow to batch records and standard operating procedures.
The inspection found a clear commitment at Artemis to strengthen local pharmaceutical manufacturing capacity, while also highlighting a few areas to keep building on–among them documentation control, training, contamination prevention, and audit readiness.
Following the walkthrough, both teams discussed the facility’s strengths and the opportunities ahead, including quality assurance, production capacity, and the shared value of local manufacturing in improving access to safe, effective, and affordable medicines across Nigeria.
Next steps include a detailed inspection report, assigned owners and timelines for follow-up actions, continued internal audits, and strengthened training records–all part of Artemis’s ongoing push to sustain GMP compliance and deepen its collaboration with Dr. Reddy’s.
